BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

Summary

BioMarin and n-Lorem Foundation entered an early research collaboration to develop a potential first-in-disease antisense oligonucleotide for ReNU Syndrome, a newly identified genetic disorder discovered in 2024 with no currently approved treatments.